Several commercially available immunoassays use both of these monoclonal antibodies for quantifying CA 15-3
in serum; the antibody 115D8 is used as the capture antibody, whereas DF3 serves as the detection antibody.
CEA, AFP, HCG, PSA, CA 125, CA 15-3
, and CA 19-9) are discussed as well as potentially useful markers for the future.
29 as tracer while CA 15-3
RIA is a dual monoclonal sandwich assay.
The sensitivity of CA 15-3
and CA 12-5 kits is 5 U/ml and that of f-PSA kit is .
Neoplastic markers (AFP, CEA, CA 19-9, CA 15-3
, CA125, TPS) were negative.
11 for AFP, [beta]-hCG, CA 125, CA 15-3
, CA 19-9 and CEA to determine whether the clinical information provided with the request corresponded to the BPAC guidelines of appropriate use.
Tumor Marker Control is intended for use as an assayed control serum to monitor the precision of laboratory-testing procedures for the analysis of AFP, CA 15-3
, CA 19-9, CA 125, CEA, Ferritin, HE4, PSA, and Free PSA.
Serum CEA and CA 15-3
as prognostic factors in primary breast cancer.
Of these, the most widely used are CA 15-3
and CEA (for review see [3,4]).
We transformed parameters that did not show a Gaussian distribution for use as dependent variables in an ANCOVA analysis; we used the natural logarithms of the serum concentrations of anti-p53, TPS, AFP, CA 15-3
, CA 125, BTA, IGF-I, and sIL-2R and the square root of the concentrations of c-erbB-2, CEA, hPLAP, and PDGF-BB.
This mulitanalyte control has three levels and features 23 tumor markers including ACTH, aldosterone, AFP, microglobulin, CA 15-3
, CA 19-9, CA 27-9, and others.
Tumor markers, such as [alpha]-fetoprotein (AFP) , carcinoembryonic antigen (CEA), cancer antigen 125 (CA 125), and CA 15-3
, can be found in the body (usually blood or urine) when cancer is present (1).